Targeted Tuberculin Testing and Treatment of Latent Tuberculosis
Return to LTBI Slide Set Main Menu
The Centers for Disease Control and Prevention (CDC) and American
Thoracic Society (ATS) issued revised guidelines for targeted tuberculin
testing and the treatment of latent tuberculosis infection (LTBI).
The guidelines were published in the June 9, 2000 issue of the Morbidity
and Mortality Weekly Report (MMWR) and in the American Journal
of Respiratory and Critical Care Medicine (2000;161:S221–S247).
In addition to changes in treatment and monitoring recommendations,
an emphasis was placed on testing only those who may have recently
been infected with tuberculosis (TB) and those at risk for progression
from latent infection to active disease. This slide set includes
the recommendations in the 2000 guidelines and updates to the recommendations
published before November 2004.
Key areas covered in this slide set include:
- Brief history of LTBI treatment
- Concept of targeted testing
- Risk factors for LTBI
- Tuberculin skin testing and QuantiFERON®-TB Test
- Treatment recommendations for LTBI
- Case studies
The target audience for this slide set is the primary healthcare
provider. Supporting references and resources have been included
in the slide set.
Adapting the presentation:
The slide can be used in its entirety or in sections depending
on audience needs. If the slides are altered, the CDC and HHS logos
must be removed.
Use of case studies:
The slide set contains three case studies to reinforce the importance
of targeted testing and the identification individuals at risk for
LTBI. The case study slides may be incorporated at the presenter’s
discretion. The question and answer slides following the case slides
can be used to encourage group participation and discussion. Alternatively,
the presenter can present the cases and highlight the main educational
points without group discussion.
DTBE - LTBI Slide Set 2005 - Introduction